Randomised phase III trial of concurrent chemoradiotherapy with extended nodal irradiation and erlotinib in patients with inoperable oesophageal squamous cell cancer
| Autor: | Dexi Du, Gang Li, Congying Xie, Hui Liu, Bing Xia, Wei Hu, Xiuhua Bian, Xuebang Zhang, Hao Jiang, Jianhua Wang, Ming Chen, Zhi-Feng Tian, Xilong Lian, Wen-feng Li, Duojie Li, Lvhua Wang, Anping Zheng, Fu-Jun Zhao, Ke-Wei Huang, Shixiu Wu, Bangxian Tan, Lin Du, Hong-Bo Zhang, Ni Zhang, Zhao Jing, Jin Hu, Honglei Luo, Ruifei Xie, Ping Zhang, Hongyan Zhang, Conghua Xie |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Adult Male Cancer Research medicine.medical_specialty Esophageal Neoplasms Paclitaxel medicine.medical_treatment Gastroenterology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged Cisplatin Chemotherapy Lymphatic Irradiation business.industry Incidence (epidemiology) Chemoradiotherapy Middle Aged Prognosis Rash Radiation therapy Survival Rate 030104 developmental biology Oncology chemistry 030220 oncology & carcinogenesis Carcinoma Squamous Cell Female Erlotinib medicine.symptom business medicine.drug Follow-Up Studies |
| Zdroj: | European journal of cancer (Oxford, England : 1990). 93 |
| ISSN: | 1879-0852 |
| Popis: | Background This randomised phase III study was conducted to investigate the efficacy of extended nodal irradiation (ENI) and/or erlotinib in inoperable oesophageal squamous cell cancer (ESCC). Patients and methods Patients with histologically confirmed locally advanced ESCC or medically inoperable disease were randomly assigned (ratio 1:1:1:1) to one of four treatment groups: group A, radiotherapy adoption of ENI with two cycles of concurrent TP chemotherapy (paclitaxel 135 mg/m2 day 1 and cisplatin 20 mg/m2 days 1–3, every 4 weeks) plus erlotinib (150 mg per day during chemoradiotherapy); group B, radiotherapy adoption of ENI with two cycles of concurrent TP; group C, radiotherapy adoption of conventional field irradiation (CFI) with two cycles of concurrent TP plus erlotinib; group D, radiotherapy adoption of CFI with two cycles of concurrent TP. Results A total of 352 patients (88 assigned to each treatment group) were enrolled. The 2-year overall survival rates of group A, B, C and D were 57.8%, 49.9%, 44.9% and 38.7%, respectively (P = 0.015). Group A significantly improved 2-year overall survival compared with group D. The ENI significantly improved overall survival in patients with inoperable ESCC (P = 0.014). The addition of erlotinib significantly decreased loco-regional recurrence (P = 0.042). Aside from rash and radiation oesophagitis, the incidence of grade 3 or greater toxicities did not differ among 4 groups. Conclusion Chemoradiotherapy with ENI and erlotinib might represent a substantial improvement on the standard of care for inoperable ESCC. ENI alone should be adopted in concurrent chemoradiotherapy for ESCC patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect